PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
522.30%
G&A growth while TRAW reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses change of 3069944.64% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
230.56%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
230.56%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
243.75%
Interest expense growth while TRAW reduces costs. John Neff would investigate differences.
418.75%
D&A growth above 1.5x TRAW's 16.00%. Michael Burry would check for excessive investment.
-202.01%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Other expenses reduction while TRAW shows 100.51% growth. Joel Greenblatt would examine advantage.
-176.90%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-176.90%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
89.62%
Similar EPS growth to TRAW's 100.00%. Walter Schloss would investigate industry trends.
89.62%
Similar diluted EPS growth to TRAW's 100.00%. Walter Schloss would investigate industry trends.
2567.99%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
2567.99%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.